DNAY - Codex DNA partners with Pfizer to advance the DNA platform

Codex DNA (NASDAQ:DNAY) is trading ~8.1% higher in the pre-market after the company announced an agreement with Pfizer (NYSE:PFE) to jointly advance its synthetic DNA platform BioXP. Under the Research Collaboration and License Agreement, the duo will collaborate to enhance the BioXP platform and use the improved system to produce assets of interest for Pfizer (PFE). Per the term, Codex DNA (DNAY) will own the improved platform and the relevant IP rights while Pfizer (PFE) will take ownership of its outputs and their IP rights, the company said in a regulatory filing Wednesday. In return, the pharma giant will pay an upfront payment of $8M for Codex DNA (DNAY) in addition to $10M in near-term milestone payments linked to the conduct of the R&D program.

For further details see:

Codex DNA partners with Pfizer to advance the DNA platform